# US 10,245,298 B2 · Compositions and methods for treating fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,245,298 B2
- Document ID: US10245298B2
- Status: Granted
- Kind: B2
- Application number: 15/460,151
- Filed: 2017-03-15
- Published: 2017-07-06
- Granted: 2019-04-02
- Earliest claimed: 2014-09-18
- Assignees: Cedars-Sinai Medical Center; The Board of Trustees of the Leland Stanford Junior University
- Applicants: Cedars-Sinai Medical Center; The Board of Trustees of the Leland Stanford Junior University
- Inventors: Ramachandran Murali; Aida Habtezion; Stephen J. Pandol
- Web page: https://patentgrep.com/patent/US10245298B2

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61N 5/1001: {using radiation sources introduced into or applied onto the body; brachytherapy}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- C07K 14/5406: {IL-4}
- C07K 14/5437: {IL-13}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.

## Claims

### Claim 1

A pharmaceutical composition comprising: a IL-4/IL-13 receptor inhibitor; and (ii) a pharmaceutically acceptable carrier, wherein the IL-4/IL-13 receptor inhibitor is CSRM53567 comprising of the amino acid sequence Tyr-Cys-Asp-Asp-Phe-Val-Gly-Ser-Phe-Asp-Cys-Tyr (SEQ ID NO: 1).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the IL-4/IL-13 receptor inhibitor is attached to moieties that result in PEGylation, glycosylation, lipidation, acetylation, amidation, end-capping modification, adding cyano groups, phosphorylation, or cyclization of the inhibitor.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the end-capping modification comprises acetylation at the N-terminus, N-terminal acylation, or N-terminal formylation.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the end-capping modification comprises amidation at the C-terminus, introduction of C-terminal alcohol, aldehyde, ester, or thioester moieties.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the IL-4/IL-13 receptor inhibitor is attached to moieties that result in extension of half-life of the inhibitor.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the moieties that result in extension of half-life of the inhibitor is Fc domain or serum albumin.